40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions
A final tranche of €12 million will follow, contingent on positive pivotal study results, with the share price calculated according to an agreed formula
BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem
Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore
Occlutech develops, manufactures, and commercialises medical devices for congenital heart disease, stroke prevention, and heart failure
The collaboration is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research
The move follows AstraZeneca’s previously announced plan to complete a direct listing of its Ordinary Shares and debt securities on the New York Stock Exchange
The new investment will fuel expansion of Avalon's Diagnostic Intelligence capabilities
The proceeds from the ?IP will be primarily utilized to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Limited
Subscribe To Our Newsletter & Stay Updated
